Compass Pathways plc (NASDAQ: CMPS) announced that its second Phase 3 trial of COMP360 psilocybin therapy met the primary endpoint ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE